There is a paucity of evidence on the subject with complete absence of RCTs. The studies support MFMS as a safe alternative in the management of high-risk TAAA. MFMS maintains branch vessel patency when used in accordance to the IFU. MFMS should not be used outside the IFU as undesirable outcomes have been reported. A personalised approach is advised considering patient comorbidities and wishes. a r t i c l e i n f o 
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in a previous publication [1] .
Clinical scenario
You have been referred an 85-year-old man with an asymptomatic thoracoabdominal aortic aneurysm (TAAA) type II (Crawford's classification) diagnosed on computed tomography angiogram with a maximum diameter of 68 mm in the descending aorta. Comorbidities include chronic obstructive pulmonary disease (COPD), obesity, diabetes mellitus type II, hypertension, and chronic renal failure. The patient tells you that in view of his age and comorbidities he is keen for a minimally invasive approach and asks you whether endovascular treatment with insertion of multilayer flow modulator stents (MFMS), a new treatment which his family read about on Google, would be a suitable option for him. To confirm the therapeutic option and achieve the best possible outcome in this high-risk patient, you perform a literature review yourself. In addition, the reference lists of the relevant papers were searched. The search was current as of 23rd January 2017.
Three-part question
In
Search outcome
Twenty seven papers were identified using the reported search. Two authors (C.P. and G.G.) independently assessed the titles and abstracts of the identified articles to determine potential relevance. Any disagreement was resolved by discussion or with the opinion of the senior author (T.A.) After reviewing the abstracts, 21 papers were selected to be fully appraised in view of relevance and methods used. From these, 2 were short communications, 2 involved overlap of patient groups (the most recent was included), 6 were irrelevant, one was a narrative review, and one article was in French (all excluded except for the latter). Inclusion criteria included studies of any size, prospective or retrospective in design that assessed outcomes for patients with thoracoabdominal aneurysm. All patients included had to have received appropriate treatment. Exclusion criteria included studies reporting on patients with peripheral or visceral aneurysms. Narrative review articles and studies where the patients had not been sub-grouped according to the anatomical site of the aneurysm to allow distilling of the evidence specifically for thoracoabdominal aneurysms were also excluded. Based on design, number of patients and origin (high volume/specialised centres and national registries) 11 papers were chosen as representative to answer the clinical question.
Results
The results of the 11 papers (one meta-analysis, 4 prospective studies, and 6 retrospective studies) are summarised in Table 1 .
Discussion
In 2016, Hynes et al. [2] published a meta-analysis of MFMS reviewing data on 171 patients with complex aortic pathology (59.1% had TAAA). They found that the aneurysm-related survival rate was 78.7% at 1 year and 66.6% at 18 months. At 18 months, this rate was 93.3% within the instructions for use (IFU) subgroup in contrast to a rate of 25.6% for patients treated outside the IFU. Technical success was 76.6%, with 95.5% of technical failures occurring in cases performed outside the IFU. All-cause survival rate was 53.7% at 1 year and 37.4% at 18 months. There were no cases of spinal cord ischemia, renal insult or stroke.
Lowe et al. [3] analysed the outcomes of MFMS in 14 patients. Among these, 50% had TAAA. All-cause, aneurysm-related and growth-free survivals were 79%, 86% and 28.5% respectively at 1 year. The 30-day mortality was 7% whilst at a mean follow-up of 22.8 months it reached 50% with one rupture. There were MFMS dislocations in 28.6% of patients with 35% of cases requiring reintervention.
In their prospective study, Bouayed et al. [4] assessed the effects of use of MFMS in 41 aortic lesions. Among these, 20 were TAAA. 30-day mortality was 5.26% due to aneurysmal rupture and myocardial infarction whilst 12-month mortality was 23.68%. The aneurysmal sac was not supplied in 30% of TAAA cases and poorly supplied in 70%. Visceral patency was 100%.
Vaislic et al. [5] evaluated one-year outcomes following the use of MFMS in 23 patients with type II and III TAAA. At 12 months, all-cause mortality was 4%, complete sac thrombosis was achieved in 75% of patients and branch patency rate was 96.5%. Moreover, at 12 months there were reinterventions in 22% of patients and the aneurysm diameter increased in 10% whilst remained stable in 90%.
Sultan et al. [6] presented the results of 103 patients treated with MFMS under IFU. Among the cases, 72.8% had TAAA. At 1 year, aneurysm-related survival was 91.7% (no rupture occurred), all-cause survival was 86.8% and the covered branch patency was 95.3%. The incidence of stroke and paraplegia were 1.9% and 0.99% respectively at 12 months.
In another study, Sultan et al. [7] appraised the consequences of treatment with MFMS outside the IFU in 38 patients, among which 39.5% had TAAA. During the follow up (10.0 ± 6.9 months), all-cause mortality was 89.5%, of which 71.1% were aneurysm-related. At 18 months, overall survival, freedom from aneurysm-related death and rupture-free survival were 17.5%, 25.0% and 31.5% respectively. Visceral branch occlusions were observed in 21% of patients. There were no reported cases of stroke or paraplegia.
Sultan and Hynes [8] retrospectively reviewed 1-year results of 55 patients, of which 56.4% had TAAA, treated with MFMS. At 1 year, aneurysm-related survival was 93.7% (no rupture occurred), all-cause survival was 84.8%, intervention-free survival was 92.4%, and all side branches were patent. Complications included bleeding (7.3%), stroke (3.6%) and reintervention (7.3%).
Henry et al. [9] analysed the use of MFMS in 18 patients (55.5% of which had TAAA). Technical success was 100% and 30-day mortality was 0%. At 8 months, aneurysm-related and all-cause survivals were 100% and 83.3% respectively, with branch patency rate being 100%. In the TAAA group, the mean aneurysm diameter decreased at 6 months.
Pane et al. [10] , Debing et al. [11] , and Polydorou et al. [12] all reported similar outcomes following treatment of TAAA with MFMS. They concluded that use of the medical device is feasible and seems to be a solution for the management of TAAA. The authors also inferred that MFMS can stabilize aneurysm diameter and ensure the patency of collateral vessels.
When looking collectively at the existing evidence, there are certain important points for consideration. First and foremost, there is a complete absence of randomised controlled trials (RCTs) on the subject. Secondly, there are no long-term follow-up studies. Thirdly, a significant amount of heterogeneity exists in terms of the variety concerning both the anatomy (location) and pathology (type) of aneurysms treated with MFMS. As a result, certain studies contradict others, especially when it comes to reporting mid-term results with some authors concluding that "the treatment of Reintervention at 1 year -7.3%
Technical success of 98.2%
Total average increase in sac volume at 1 year -3.26%
The ratio of thrombus to total volume stayed almost constant over the 12 months at 0.48
The ratio of flow to total volume fell from 0.21 to 0.12 at 12 months (p ¼ 0.069)
Conclusions

MFMS implantation instigates a process of aortic remodelling involving initial thrombus deposition
Increasing sac size did not lead to rupture
The MFMS offers promise for resolution of complex thoracoabdominal pathology with offthe-shelf availability
Further development and technical refinement is required
Long-term follow-up of the registry patients is mandatory before establishing a randomised controlled study
Limitations
Brevity of follow-up study Variation in the pathologies and anatomies of the patients treated Issues of registry: data collection, patient compliance and the variety of follow-up protocols and pharmacotherapies Henry et al. [9] , France aneurysms with MFMS seems to have encouraging midterm results" [10] whilst others reporting that "the role of MFMS remains unclear" [3] . Despite the many limitations in the literature, there seems to be a consensus that MFMS, when used within their IFU, may represent a valuable option in those patients where open surgery is deemed high-risk. Finally, existing studies also concur that in addition to robust scientific and clinical data, further innovative developments are needed to improve MFMS safety, expand their instructions for use, and enhance their efficacy.
Clinical bottom line
In addition to the mortality associated with open TAAA repair, fundamental risks include compromising the blood flow to the spinal cord and/or viscera. In this context, MFMS appear to represent a safe alternative in the management of complex aneurysms. In this paper, the outcomes in patients with TAAA undergoing endovascular repair with MFMS were evaluated. Several studies showed that the use of MFMS in the treatment of TAAA is associated with a low incidence of complications, including stroke, paraplegia and aneurysm rupture. In addition, these studies demonstrated acceptable rates of aneurysm-related survival and visceral branch patency. On the other hand, undesirable outcomes have been reported when the MFMS is used outside the IFU.
Thus, we conclude that endovascular treatment with MFMS insertion is a safe treatment for TAAA in high-risk patients, associated with maintenance of branch vessel patency, provided they are used in accordance to the IFU. However, a number of limitations must be considered when interpreting this evidence. Firstly, the complete lack of RCTs, secondly, the absence of long-term followup studies, and thirdly, the heterogeneity of the pathologies among the different populations studied. Despite these limitations, MFMS appear to offer a suitable and safe alternative to open surgery for TAAA cases where open surgery is deemed high-risk.
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